The Alliance for Clinical Trials in Oncology was formed in March 2011 by the merger of the American College of Surgeons Oncology Group (ACOSOG), the Cancer, Leukemia Group B (CALGB) and the North Central Cancer Treatment Group (NCCTG). The merger of these cooperative groups reflects the call in April 2010 from the Institute of Medicine to strengthen and streamline operations among NCI clinical trials cooperative group programs. In June 2010, ACOSOG, CALGB and NCCTG integrated their statistical, data management and information technology functions. In November 2010, NCI announced plans to transform the clinical trials system by reducing the number of adult cooperative groups from nine to four. Having already merged some functions, the three groups began evaluating the possibility of full integration to further streamline operations, expand their scientific research opportunities and apply for funding as a new, larger cooperative group.
In June 2011, governing boards of ACOSOG, CALGB and NCCTG endorsed a proposed Alliance constitution, bylaws and transition plan. The Transition Alliance Board of Directors then ratified the constitution and elected a new group chair, Monica M. Bertagnolli, MD, along with board members to serve on the executive committee. The first Alliance group meeting was held in November 2011 in Chicago.
The Alliance for Clinical Trials in Oncology is governed by a board of directors and executive committee, and led by a group chair and principal investigator. It is organized into five programs, each led by a co-principal investigator. These programs include the Statistics and Data Management Program, Central Protocol Operations Program, Translational Research Program, Cancer Control Program and the American College of Surgeons Clinical Research Program.